Researcher
Hans Van Vlierberghe
- Keywords:liver transplantation, hepatocellular carcinoma, liver diseases
- Disciplines:Cancer diagnosis, Cancer prevention, Cancer epidemiology, Cancer biology, Cancer therapy, Gastro-enterology and hepatology not elsewhere classified, Hepatology (incl. pancreas), Oncology not elsewhere classified, Gastro-enterology, Hepatology
Affiliations
- Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Internal medicine (Department)
Member
From1 Oct 2003 → 30 Sep 2018
Projects
1 - 10 of 19
- Development of cell-interactive and biodegradable AUP-based hydrogel materials for the fabrication of three-dimensional liver tissue engineering scaffoldsFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Optimising the Human Detection of Cancer within Colorectal Polyps with a Simple Clinical AlgorithmFrom1 Oct 2023 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Deubiquitinase UCHL1 targeting as part of new combinatorial treatments for hepatocellular carcinoma: a preclinical assessmentFrom1 Oct 2022 → TodayFunding: Nonprofit institution or equivalents
- SpatialConnect: linking tissue biology to the new era of single-cell spatial transcriptomicsFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- The role of Kupffer cells in the pathogenesis of hepatocellular carcinoma.From1 Nov 2021 → 31 Oct 2022Funding: Nonprofit institution or equivalents
- Immune profiling and the role of monocyte/macrophage populations in primary sclerosing cholangitis and related ulcerative colitisFrom1 Nov 2021 → TodayFunding: FWO fellowships
- Immune profiling and the role of monocyte/macrophage populations in primary sclerosing cholangitis and related ulcerative colitis.From1 Oct 2021 → 31 Oct 2021Funding: BOF - doctoral mandates
- Dual targeting of CCr2 and CCR5 as thearpy for hepatocellular carcinoma: can we break immune tolerance?From1 Oct 2018 → 30 Sep 2022Funding: Nonprofit institution or equivalents
- Replacement of N-glycan analysis equipmentFrom1 Jun 2018 → 31 May 2020Funding: BOF - Other initiatives
- Startersbeurs Helena Degroote: The origin of tumor-associated macrophages and the therapeutic potential of dual targeting CCR2 and CCR5 as therapy for hepatocellular carcinomaFrom1 Oct 2017 → 30 Sep 2018Funding: Nonprofit institution or equivalents
Publications
21 - 30 of 103
- Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin(2018)
Authors: Jordan J Feld, David E Bernstein, Ziad Younes, Hans Van Vlierberghe, Lois Larsen, Fernando Tatsch, Peter Ferenci
Pages: 1571 - 1575 - The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma(2018)
Authors: Daniela Pollutri, Clarissa Patrizi, Sara Marinelli, Catia Giovannini, Elena Trombetta, Ferdinando A Giannone, Maurizio Baldassarre, Santina Quarta, Yves-Paul Vandewynckel, Aster Vandierendonck, et al.
- Severe hepatic and pulmonary involvement in Rendu-Osler-Weber syndrome(2018)
Authors: Xavier Verhelst, Anja Geerts, Hans Van Vlierberghe, Peter Smeets, CLARISSE LECLUYSE
Pages: 13 - 18 - Epidemiology, cause, evolution and outcome in a cohort of 1177 critically ill patients with hypoxic hepatitis(2017)Volume: 5
Authors: Laura Van Coile, Astrid Van den broecke, Hans Van Vlierberghe, Kirsten Colpaert, Johan Decruyenaere
Pages: 515 - 516 - Pharmacokinetic interactions between simeprevir and ledipasvir in treatment naive hepatitis C virus genotype 1-Infected patients without cirrhosis treated with a simeprevir-sofosbuvir-ledipasvir regimen(2017)
Authors: Stefan Bourgeois, Yves Horsmans, Frederik Nevens, Hans Van Vlierberghe, Christophe Moreno, Maria Beumont, Leen Vijgen, Veerle van Eygen, Donghan Luo, Vera Hillewaert, et al.
- Modulation of the unfolded protein response by tauroursodeoxycholic acid counteracts apoptotic cell death and fibrosis in a mouse model for secondary biliary liver fibrosis(2017)
Authors: Annelies Paridaens, Sarah Raevens, Lindsey Devisscher, Eliene Bogaerts, Xavier Verhelst, Anne Hoorens, Hans Van Vlierberghe, Leo van Grunsven, Anja Geerts, Isabelle Colle
- Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma(2017)
Authors: Nicola Personeni, Laura Giordano, Giovanni Abbadessa, Camillo Porta, Ivan Borbath, Bruno Daniele, Jean-Luc Van Laethem, Hans Van Vlierberghe, Joerg Trojan, Enrico N. De Toni, et al.
Pages: 14408 - 14415 - Global prevalence and genotype distribution of hepatitis C virus infection in 2015 : a modelling study(2017)
Authors: Sarah Blach, Stefan Zeuzem, Michael Manns, Ibrahim Altraif, Ann-Sofi Duberg, David H. Muljono, Imam Waked, Seyed M. Alavian, Mei-Hsuan Lee, Francesco Negro, et al.
Pages: 161 - 176 - Development of a multivariate prediction model for mortality in a cohort of 1177 critically ill patients with hypoxic hepatitis(2017)Volume: 5
Authors: Astrid Van den broecke, Laura Van Coile, Hans Van Vlierberghe, Kirsten Colpaert, Johan Decruyenaere
Pages: 515 - 515 - Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial(2016)
Authors: Michael Manns, Didier Samuel, Edward J Gane, David Mutimer, Geoff McCaughan, Maria Buti, Martín Prieto, José Luis Calleja, Markus Peck-Radosavljevic, Beat Mullhaupt, et al.
Pages: 685 - 697